EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID

Lourdes Mateu, Louise L Hansen, Joao Pedro Carmezim, Cora Loste, Tommaso Francesco Aiello, Gemma Lladós, Jose Ramon Santos, Edwards Pradenas, Benjamin Trinité, Cristina Herrero, Anna Garcia, Anna Gervassi und 9 weitere

Clinical Microbiology and Infection · 2026-09 · 32 (9) · 1487-1494

DOI: 10.1016/j.cmi.2026.06.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Microbiology and Infection, 2026-09. Verfasst von Lourdes Mateu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain; Fundació Lluita contra les Infeccions, Badalona, Spain…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antigens, Viral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca PLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: SARS-CoV-2 antigens have been detected in plasma months after acute infection, but their long-term dynamics and clinical relevance remain unclear. We aimed to assess the persistence and clinical specificity of plasma SARS-CoV-2 antigenemia over 2 years after acute infection. METHODS: We conducted a 2-year longitudinal study involving 425 adults who developed Long COVID (n = 167) or fully recovered from acute COVID-19 (n = 148), and uninfected controls (n = 110). Plasma samples were collected at 6-12 months and 18-24 months after infection. SARS-CoV-2 spike, S1 subunit, and nucleocapsid antigens were quantified using the ultrasensitive Simoa® platform blinded for clinical features. SARS-CoV-2 specific humoral responses, including neutralizing antibodies, were also assessed. RESULTS: At 6-12 months, SARS-CoV-2 antigenemia (any antigen) was detected in 31% of individuals with Long COVID, in 20% of those fully recovered and in 5.4% of uninfected controls. By 18-24 months, positivity declined to 3.5%, 0%, and 1.5%, respectively. Full spike was the most frequent antigen detected, whereas S1 was rarely observed and nucleocapsid was absent in recovered participants. Antigenemia was not associated with number or type of persistent symptoms, antibody titres, including neutralizing capacity, or vaccination status. CONCLUSIONS: SARS-CoV-2 antigens circulate in plasma up to 1 year after infection in a minority of individuals, regardless of whether they develop Long COVID or not, and become rarely detectable later on. Therefore, current evidence does not support its use to guide clinical monitoring or treatment decisions in Long COVID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antigens, ViralHumansLongitudinal StudiesFemaleMiddle AgedAntibodies, ViralMaleAdultAntibodies, NeutralizingPost-Acute COVID-19 SyndromeAgedSpike Glycoprotein, CoronavirusCoronavirus Nucleocapsid ProteinsPhosphoproteins

Stichwörter der Autor:innen

AntigenemiaLong COVIDPost-COVID-19 conditionPostacute sequelae of SARS-CoV-2 (PASC)SARS-CoV-2 persistence

Substanzen

Antibodies, ViralAntigens, ViralAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Coronavirus Nucleocapsid ProteinsPhosphoproteins

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain; Fundació Lluita contra les Infeccions, Badalona, Spain; Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain; Uni…
  • Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Biostatistics Support and Research Unit, Germans Trias i Pujol Research Institute and Hospital (IGTP), Catalonia, Spain.
  • Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain; Fundació Lluita contra les Infeccions, Badalona, Spain; Universitat de Vic - Universitat Central de Catalunya, Vic, Cataloni…
  • Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain; Fundació Lluita contra les Infeccions, Badalona, Spain.
  • Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain; Fundació Lluita contra les Infeccions, Badalona, Spain; Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain; Red…

Förderung

  • AstraZeneca PLC

Zitieren

APA

Mateu, L., Hansen, L. L., Carmezim, J. P., Loste, C., Aiello, T. F., Lladós, G., Santos, J. R., Pradenas, E., Trinité, B., Herrero, C., Garcia, A., Gervassi, A., Puig, T., Grau, E., Carrillo, J., Blanco, J., Kijak, G. H., Tebé, C., Paredes, R., …, & Massanella, M. (2026). Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID. Clinical Microbiology and Infection, 32(9), 1487-1494. https://doi.org/10.1016/j.cmi.2026.06.014

Vancouver

Mateu L, Hansen LL, Carmezim JP, Loste C, Aiello TF, Lladós G, et al. Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID. Clinical Microbiology and Infection. 2026;32(9):1487-1494. doi:10.1016/j.cmi.2026.06.014

BibTeX
@article{Mateu2026,
  author = {Mateu, Lourdes and Hansen, Louise L and Carmezim, Joao Pedro and Loste, Cora and Aiello, Tommaso Francesco and Lladós, Gemma and Santos, Jose Ramon and Pradenas, Edwards and Trinité, Benjamin and Herrero, Cristina and Garcia, Anna and Gervassi, Anna and Puig, Teresa and Grau, Eulàlia and Carrillo, Jorge and Blanco, Julià and Kijak, Gustavo H and Tebé, Cristian and Paredes, Roger and Walt, David R and Massanella, Marta},
  title = {Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID},
  journal = {Clinical Microbiology and Infection},
  year = {2026},
  volume = {32},
  number = {9},
  pages = {1487--1494},
  doi = {10.1016/j.cmi.2026.06.014}
}
Kostenlos starten →